Search

Your search keyword '"Pouleur, Anne-Catherine"' showing total 474 results
Start Over Author "Pouleur, Anne-Catherine"
474 results on '"Pouleur, Anne-Catherine"'

3. Impact of progressive aortic regurgitation on outcomes after left ventricular assist device implantation

Author

Gasparovic, Hrvoje, Jakus, Nina, Brugts, Jasper J., Pouleur, Anne-Catherine, Timmermans, Philippe, Rubiś, Pawel, Gaizauskas, Edvinas, Van Craenenbroeck, Emeline M., Barge-Caballero, Eduardo, Grundmann, Sebastian, Paolillo, Stefania, D’Amario, Domenico, Braun, Oscar Ö., Meyns, Bart, Droogne, Walter, Wierzbicki, Karol, Holcman, Katarzyna, Planinc, Ivo, Lovric, Daniel, Flammer, Andreas J., Petricevic, Mate, Biocina, Bojan, Lund, Lars H., Milicic, Davor, Ruschitzka, Frank, and Cikes, Maja

Published
2022
Full Text
View/download PDF

6. Impact of early versus class I–triggered surgery on postoperative survival in severe aortic regurgitation: An observational study from the Aortic Valve Insufficiency and Ascending Aorta Aneurysm International Registry

Author

Hanet, Vincent, Schäfers, Hans-Joachim, Lansac, Emmanuel, de Kerchove, Laurent, El Hamansy, Ismail, Vojácek, Jan, Contino, Monica, Pouleur, Anne-Catherine, Beauloye, Christophe, Pasquet, Agnès, Vanoverschelde, Jean-Louis, Vancraeynest, David, and Gerber, Bernhard L.

Published
2023
Full Text
View/download PDF

7. Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER

Author

Wang, Xiaowen, Vaduganathan, Muthiah, Claggett, Brian L., Hegde, Sheila M., Pabon, Maria, Kulac, Ian J., Vardeny, Orly, O’Meara, Eileen, Zieroth, Shelley, Katova, Tzvetana, McGrath, Martina M., Pouleur, Anne-Catherine, Jhund, Pardeep S., Desai, Akshay S., Inzucchi, Silvio E., Kosiborod, Mikhail N., de Boer, Rudolf A., Kober, Lars, Sabatine, Marc S., Martinez, Felipe A., Ponikowski, Piotr, Shah, Sanjiv J., Hernandez, Adrian F., Langkilde, Anna Maria, McMurray, John J.V., Solomon, Scott D., and Lam, Carolyn S.P.

Published
2023
Full Text
View/download PDF

8. Clinical and Hemodynamic Effects of Percutaneous Edge-to-Edge Mitral Valve Repair in Atrial Versus Ventricular Functional Mitral Regurgitation

Author

Claeys, Marc J., Debonnaire, Philippe, Bracke, Veronique, Bilotta, Giada, Shkarpa, Nikol, Vanderheyden, Marc, Coussement, Patrick, Vanderheyden, Jan, de Heyning, Caroline M. Van, Cosyns, Bernard, Pouleur, Anne-Catherine, Lancellotti, Patrizio, Paelinck, Bernard P., Ferdinande, Bert, and Dubois, Christophe

Published
2021
Full Text
View/download PDF

9. SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule

Author

Aboubakar, Frank, Acid, Souad, Amini, Nadia, Bailly, Sarah, Beauloye, Christophe, Castanares-Zapatero, Diego, Coche, Emmanuel, Collienne, Christine, Cornette, Pascale, De Brauwer, Isabelle, Dechamps, Mélanie, Dupriez, Florence, Froidure, Antoine, Garnir, Quentin, Gerber, Bernhard, Ghaye, Benoît, Gilard, Isabelle, Gohy, Sophie, Grégoire, Charles, Hantson, Philippe, Jacquet, Luc-Marie, Kabamba, Benoit, Kautbally, Shakeel, Lanthier, Nicolas, Larbaoui, Fatima, Liistro, Giuseppe, Maes, Frédéric, Montiel, Virginie, Mwenge, Benny, Pierard, Sophie, Pilette, Charles, Pouleur, Anne Catherine, Sogorb, Amaury, Starkel, Peter, Rodriguez-Villalobos, Hector, Thoma, Maximilien, Van Caeneghem, Olivier, Vancraeynest, David, Werion, Alexis, Belkhir, Leila, Perrot, Marie, Schmit, Gregory, Aydin, Selda, Chen, Zhiyong, Penaloza, Andrea, De Greef, Julien, Yildiz, Halil, Pothen, Lucie, Yombi, Jean Cyr, Dewulf, Joseph, Scohy, Anais, Gérard, Ludovic, Wittebole, Xavier, Laterre, Pierre-François, Miller, Sara E., Devuyst, Olivier, Jadoul, Michel, and Morelle, Johann

Published
2020
Full Text
View/download PDF

10. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study

Author

Gniot, Jacek, Mozheiko, Maria, Lelonek, Malgorzata, Dominguez, Antonio Reyes, Horacek, Thomas, Garcia del Rio, Enrique, Kobalava, Zhanna, Mueller, Christian Eugen, Cavusoglu, Yuksel, Straburzynska-Migaj, Ewa, Slanina, Miroslav, vom Dahl, Juergen, Senni, Michele, Ryding, Alisdair, Moriarty, Andrew, Robles, Manuel Beltran, Villota, Julio Nunez, Quintana, Antonio Garcia, Nitschke, Thorsten, Garcia Pinilla, Jose Manuel, Bonet, Luis Almenar, Chaaban, Said, Filali zaatari, Samia, Spinar, Jindrich, Musial, Wlodzimierz, Abdelbaki, Khaled, Belohlavek, Jan, Fehske, Wolfgang, Bott, Michael Carlos, Hoegalmen, Geir, Leiro, Marisa Crespo, Ozcan, Ismail Turkay, Mullens, Wilfried, Kryza, Radim, Al-Ani, Riadh, Loboz-Grudzien, Krystyna, Ermoshkina, Lyudmila, Hojerova, Silvia, Fernandez, Alberto Alfredo, Spinarova, Lenka, Lapp, Harald, Bulut, Efraim, Almeida, Filipa, Vishnevsky, Alexander, Belicova, Margita, Pascual, Domingo, Witte, Klaus, Wong, Kenneth, Droogne, Walter, Delforge, Marc, Peterka, Martin, Olbrich, Hans-Georg, Carugo, Stefano, Nessler, Jadwiga, McGill, Thao Huynh, Huegl, Burkhard, Akin, Ibrahim, Moreira, Ilidio, Baglikov, Andrey, Thambyrajah, Jeetendra, Hayes, Chris, Barrionuevo, Marcelo Raul, Yigit, Zerrin, Kaya, Hakki, Klimsa, Zdenek, Radvan, Martin, Kadel, Christoph, Landmesser, Ulf, Di Tano, Giuseppe, Lisik, Malgorzata Buksinska, Fonseca, Candida, Oliveira, Luis, Marques, Irene, Santos, Luis Miguel, Lenner, Egon, Letavay, Peter, Bueno, Manuel Gomez, Mota, Paula, Wong, Aaron, Bailey, Kristian, Foley, Paul, Hasbani, Eduardo, Virani, Sean, Massih, Tony Abdel, Al-Saif, Shukri, Taborsky, Milos, Kaislerova, Marta, Motovska, Zuzana, Cohen, Aron Ariel, Logeart, Damien, Endemann, Dierk, Ferreira, Daniel, Brito, Dulce, Kycina, Peter, Bollano, Entela, Basilio, Enrique Galve, Rubio, Lorenzo Facila, Aguado, Marcos Garcia, Schiavi, Lilia Beatriz, Zivano, Daniel Francisco, Lonn, Eva, El Sayed, Ali, Pouleur, Anne-Catherine, Heyse, Alex, Schee, Alexandr, Polasek, Rostislav, Houra, Marek, Tribouilloy, Christophe, Seronde, Marie France, Galinier, Michel, Noutsias, Michel, Schwimmbeck, Peter, Voigt, Ingo, Westermann, Dirk, Pulignano, Giovanni, Vegsundvaag, Johnny, Da Silva Antunes, Jose Alexandre, Monteiro, Pedro, Stevlik, Jan, Goncalvesova, Eva, Hulkoova, Beata, Castro Fernandez, Antonio Juan, Davies, Ceri, Squire, Iain, Meyer, Philippe, Sheppard, Richard, Sahin, Tayfun, Sochor, Karel, De Geeter, Guillaume, Wachter, Rolf, Schmeisser, Alexander, Weil, Joachim, Soares, Ana Oliveira, Vasilevna, Olga Bulashova, Oshurkov, Andrey, Sunderland, Shahid Junejo, Glover, Jason, Exequiel, Tomas, Decoulx, Eric, Meyer, Sven, Muenzel, Thomas, Frioes, Fernando, Arbolishvili, Georgy, Tokarcikova, Anna, Karlstrom, Patric, Trullas Vila, Joan Carles, Perez, Gonzalo Pena, Sankaranarayanan, Rajiv, Nageh, Thuraia, Alasia, Diego Cristian, Refaat, Marwan, Demirkan, Burcu, Al-Buraiki, Jehad, Karabsheh, Shadi, Pascual-Figal, Domingo, Bao, Weibin, Noè, Adele, Schwende, Heike, Butylin, Dmytro, and Prescott, Margaret F.

Published
2020
Full Text
View/download PDF

11. Carbohydrate antigen 125: a useful marker of congestion, fibrosis, and prognosis in heart failure with preserved ejection fraction.

Author

Menghoum, Nassiba, Badii, Maria Chiara, Deltombe, Matthieu, Lejeune, Sibille, Roy, Clotilde, Vancraeynest, David, Pasquet, Agnes, Gerber, Bernhard L., Horman, Sandrine, Gruson, Damien, Beauloye, Christophe, and Pouleur, Anne‐Catherine

Subjects
HEART failure, BRAIN natriuretic factor, VENTRICULAR ejection fraction, CARDIAC magnetic resonance imaging, FIBROBLAST growth factors, PROPORTIONAL hazards models
Abstract

Aims: Heart failure (HF) with preserved ejection fraction (HFpEF) is a disease associated with high morbidity and mortality, for which it is difficult to identify patients with the poorest prognosis in routine clinical practice. Carbohydrate antigen 125 (CA 125) has been shown to be a potential marker of congestion and prognosis in HF. We sought to better characterize HFpEF patients with high CA 125 levels by using a multimodal approach. Methods and results: We prospectively enrolled 139 HFpEF patients (78 ± 8 years; 60% females) and 25 controls matched for age and sex (77 ± 5 years; 60% females). They underwent two‐dimensional echocardiography, cardiac magnetic resonance with late gadolinium enhancement [including extracellular volume (ECV) measurement], and serum measurements of CA 125 level. The primary endpoint of the study was a composite of all‐cause mortality or first HF hospitalization. The prognostic impact of CA 125 was determined using Cox proportional hazard models. Median CA 125 levels were significantly higher in HFpEF patients compared with controls [CA 125: 23.5 (14.5–44.7) vs. 14.6 (10.3–21.0) U/mL, P = 0.004]. CA 125 levels were positively correlated with a congestion marker [N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) levels, Pearson's r = 0.37, P < 0.001] and markers of cardiac fibrosis estimated by both ECV (Pearson's r = 0.26, P = 0.003) and fibroblast growth factor 23 levels (Pearson's r = 0.50, P < 0.001). Over a median follow‐up of 49 (22–64) months, 97 HFpEF patients reached the composite endpoint. Even after adjustment for the Meta‐Analysis Global Group in Chronic risk score, a CA 125 level ≥35 U/mL was still a significant predictor of the composite endpoint [hazard ratio (HR): 1.58 (1.04–2.41), P = 0.032] and more particularly of HF hospitalization [HR: 1.81 (1.13–2.92), P = 0.014]. In contrast, NT‐proBNP levels were not an independent predictor. Conclusions: CA 125 levels were significantly higher in HFpEF patients compared with controls matched for age and sex and were associated with markers of congestion and cardiac fibrosis. CA 125 levels were a strong and independent predictor of HF hospitalization in HFpEF patients. These data suggest a potential value of CA 125 as a biomarker for staging and risk prediction in HFpEF. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Cardiac structure, function, and coronary anatomy 10 years after isolated contemporary adjuvant radiotherapy in breast cancer patients with low cardiovascular baseline risk.

Author

Krug, Pauline, Geets, Xavier, Berlière, Martine, Duhoux, François, Beauloye, Christophe, Pasquet, Agnès, Vancraeynest, David, Pouleur, Anne-Catherine, and Gerber, Bernhard L

Subjects
HEART anatomy, HEART physiology, RISK assessment, CROSS-sectional method, PEARSON correlation (Statistics), RADIOTHERAPY, T-test (Statistics), STATISTICAL significance, RESEARCH funding, BREAST tumors, BLOOD vessels, COMPUTED tomography, RESEARCH evaluation, CARDIOVASCULAR diseases risk factors, TREATMENT effectiveness, MAGNETIC resonance imaging, PEPTIDE hormones, MANN Whitney U Test, CHI-squared test, DESCRIPTIVE statistics, LONGITUDINAL method, PEPTIDES, WALKING, INTRACLASS correlation, CANCER patient psychology, CORONARY angiography, EXERCISE tests, DATA analysis software, TIME, ECHOCARDIOGRAPHY, REGRESSION analysis, INTER-observer reliability
Abstract

Aims The effects of isolated contemporary low-dose breast cancer (BC) radiotherapy (RT) on the heart remain poorly understood. This study aims to assess the long-term impacts of BC-RT on cardiac structure and function. Methods and results Seventy-six women (62 ± 7 years) without history of prior heart disease, who had undergone RT for either first left (n = 36) or right (n = 40) BC, without additional medical oncology therapy apart from hormonal treatment 11 ± 1 years earlier, underwent transthoracic echocardiography, cardiac magnetic resonance imaging (CMR), computed tomography coronary angiography (CTCA), NT-proBNP, and a 6-min walk test (6MWT). They were compared with 54 age-matched healthy female controls. By CTCA, 68% of BC patients exhibited no or very mild coronary disease, while only 11% had moderate stenosis (50–69%) and 3% had significant stenosis (>70%). Despite slightly reduced regional echocardiographic midventricular strains, BC patients exhibited similar global left and right ventricular volumes, ejection fractions, and global strains by echocardiography and CMR as controls. Mitral E/e′ ratios were slightly higher, and mitral deceleration times were slightly lower, but NT-proBNP was similar to controls. Also, 6MWT was normal. None had late gadolinium enhancement, and extracellular volume fraction was similar in BC (28 ± 3 vs. 29 ± 3, P = 0.15) and controls. No differences were observed relative to dose or side of RT. Conclusion Aside from minor alterations of regional strains and diastolic parameters, women who received isolated RT for BC had low prevalence of coronary disease, normal global systolic function, NT-proBNP, and exercise capacity and showed no structural changes by CMR, refuting significant long-term cardiotoxicity in such low-risk patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Cardiac structure, function and coronary anatomy 10 years after isolated contemporary adjuvant radiotherapy in breast cancer patients with low cardiovascular baseline risk

Author

Krug, Pauline, primary, Geets, Xavier, additional, Berlière, Martine, additional, Duhoux, François, additional, Beauloye, Christophe, additional, Pasquet, Agnès, additional, Vancraeynest, David, additional, Pouleur, Anne-Catherine, additional, and Gerber, Bernhard L, additional

Published
2023
Full Text
View/download PDF

18. Platelet Acetyl-CoA Carboxylase Phosphorylation: A Risk Stratification Marker That Reveals Platelet-Lipid Interplay in Coronary Artery Disease Patients

Author

Kautbally, Shakeel, Lepropre, Sophie, Onselaer, Marie-Blanche, Le Rigoleur, Astrid, Ginion, Audrey, De Meester de Ravenstein, Christophe, Ambroise, Jerome, Boudjeltia, Karim Z., Octave, Marie, Wéra, Odile, Hego, Alexandre, Pincemail, Joël, Cheramy-Bien, Jean-Paul, Huby, Thierry, Giera, Martin, Gerber, Bernhard, Pouleur, Anne-Catherine, Guigas, Bruno, Vanoverschelde, Jean-Louis, Kefer, Joelle, Bertrand, Luc, Oury, Cécile, Horman, Sandrine, and Beauloye, Christophe

Published
2019
Full Text
View/download PDF

20. Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease

Author

Balligand, Jean-Luc, primary, Brito, Dulce, additional, Brosteanu, Oana, additional, Casadei, Barbara, additional, Depoix, Christophe, additional, Edelmann, Frank, additional, Ferreira, Vanessa, additional, Filippatos, Gerasimos, additional, Gerber, Bernhard, additional, Gruson, Damien, additional, Hasenclever, Dirk, additional, Hellenkamp, Kristian, additional, Ikonomidis, Ignatios, additional, Krakowiak, Bartosz, additional, Lhommel, Renaud, additional, Mahmod, Masliza, additional, Neubauer, Stefan, additional, Persu, Alexandre, additional, Piechnik, Stefan, additional, Pieske, Burkert, additional, Pieske-Kraigher, Elisabeth, additional, Pinto, Fausto, additional, Ponikowski, Piotr, additional, Senni, Michele, additional, Trochu, Jean-Noël, additional, Van Overstraeten, Nancy, additional, Wachter, Rolf, additional, and Pouleur, Anne-Catherine, additional

Published
2023
Full Text
View/download PDF

21. Dual antiplatelet therapy is associated with high α-tubulin acetylation in circulating platelets from coronary artery disease patients

Author

Robaux, Valentine, primary, Kautbally, Shakeel, additional, Ginion, Audrey, additional, Dechamps, Mélanie, additional, Lejeune, Sibille, additional, Menghoum, Nassiba, additional, Bertrand, Luc, additional, Pouleur, Anne-Catherine, additional, Horman, Sandrine, additional, and Beauloye, Christophe, additional

Published
2023
Full Text
View/download PDF

24. Mean platelet volume: a prognostic marker in heart failure with preserved ejection fraction

Author

Menghoum, Nassiba, primary, Beauloye, Christophe, additional, Lejeune, Sibille, additional, Badii, Maria Chiara, additional, Gruson, Damien, additional, van Dievoet, Marie-Astrid, additional, Pasquet, Agnès, additional, Vancraeynest, David, additional, Gerber, Bernhard, additional, Bertrand, Luc, additional, Horman, Sandrine, additional, and Pouleur, Anne-Catherine, additional

Published
2023
Full Text
View/download PDF

26. Dual antiplatelet therapy is associated with high a-tubulin acetylation in circulating platelets from coronary artery disease patients.

Author

Robaux, Valentine, Kautbally, Shakeel, Ginion, Audrey, Dechamps, Mélanie, Lejeune, Sibille, Menghoum, Nassiba, Bertrand, Luc, Pouleur, Anne-Catherine, Horman, Sandrine, and Beauloye, Christophe

Subjects
PRASUGREL, PLATELET aggregation inhibitors, CORONARY artery disease, ACETYLATION, BLOOD platelets, ACUTE coronary syndrome
Abstract

Platelet inhibition is the main treatment strategy to prevent atherothrombotic complications after acute coronary syndrome or percutaneous coronary intervention. Despite dual antiplatelet therapy (DAPT) combining aspirin and a P2Y12 receptor inhibitor, high on-treatment platelet reactivity (HPR) persists in some patients due to poor response to treatment and is associated with ischemic risk. Tubulin acetylation has been pointed out as a hallmark of stable microtubules responsible for the discoid shape of resting platelets. However, the impact of antiplatelet treatments on this posttranslational modification has never been studied. This study investigated whether tubulin acetylation differs according to antiplatelet therapy and on-treatment platelet reactivity. Platelets were isolated from arterial blood samples of 240 patients admitted for coronary angiography, and levels of a-tubulin acetylation on lysine 40 (a-tubulin K40 acetylation) were assessed by western blot. We show that platelet a-tubulin K40 acetylation was significantly increased in DAPT-treated patients. In addition, the proportion of patients with high levels of a-tubulin K40 acetylation was drastically reduced among DAPT-treated patients with HPR. Multivariate logistic regression confirmed that DAPT resulting in adequate platelet inhibition was strongly associated with elevated a-tubulin K40 acetylation. In conclusion, our study highlights the role of elevated platelet a-tubulin K40 acetylation as a marker of platelet inhibition in response to DAPT. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. Sex-related differences in left ventricular assist device utilization and outcomes: results from the PCHF-VAD registry

Author

Radhoe, Sumant P, Jakus, Nina, Veenis, Jesse F, Timmermans, Philippe, Pouleur, Anne-Catherine, Rubís, Pawel, Van Craenenbroeck, Emeline M, Gaizauskas, Edvinas, Barge-Caballero, Eduardo, Paolillo, Stefania, Grundmann, Sebastian, D'Amario, Domenico, Braun, Oscar Ö, Gkouziouta, Aggeliki, Planinc, Ivo, Macek, Jana Ljubas, Meyns, Bart, Droogne, Walter, Wierzbicki, Karol, Holcman, Katarzyna, Flammer, Andreas J, Gasparovic, Hrvoje, Biocina, Bojan, Miličić, Davor, Lund, Lars H, Ruschitzka, Frank, Brugts, Jasper J, Cikes, Maja, Cardiology, University of Zurich, and Brugts, Jasper J

Subjects
advanced heart failure, left ventricular assist device, sex, survival, utilization, Male, Survival, Advanced heart failure, Heart Failure / epidemiology, Left ventricular assist device, Heart-Assist Devices / adverse effects, 610 Medicine & health, 2705 Cardiology and Cardiovascular Medicine, Utilization, Treatment Outcome, 10209 Clinic for Cardiology, Humans, Sex, Female, Heart Failure / therapy, Registries, Human medicine, Cardiology and Cardiovascular Medicine
Abstract

AIMS: Data on sex and left ventricular assist device (LVAD) utilization and outcomes have been conflicting and mostly confined to US studies incorporating older devices. This study aimed to investigate sex-related differences in LVAD utilization and outcomes in a contemporary European LVAD cohort. METHODS AND RESULTS: This analysis is part of the multicentre PCHF-VAD registry studying continuous-flow LVAD patients. The primary outcome was all-cause mortality. Secondary outcomes included ventricular arrhythmias, right ventricular failure, bleeding, thromboembolism, and the haemocompatibility score. Multivariable Cox regression models were used to assess associations between sex and outcomes. Overall, 457 men (81%) and 105 women (19%) were analysed. At LVAD implant, women were more often in Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile 1 or 2 (55% vs. 41%, P = 0.009) and more often required temporary mechanical circulatory support (39% vs. 23%, P = 0.001). Mean age was comparable (52.1 vs. 53.4 years, P = 0.33), and median follow-up duration was 344 [range 147-823] days for women and 435 [range 190-816] days for men (P = 0.40). No significant sex-related differences were found in all-cause mortality (hazard ratio [HR] 0.79 for female vs. male sex, 95% confidence interval [CI] [0.50-1.27]). Female LVAD patients had a lower risk of ventricular arrhythmias (HR 0.56, 95% CI [0.33-0.95]) but more often experienced right ventricular failure. No significant sex-related differences were found in other outcomes. CONCLUSIONS: In this contemporary European cohort of LVAD patients, far fewer women than men underwent LVAD implantation despite similar clinical outcomes. This is important as the proportion of female LVAD patients (19%) was lower than the proportion of females with advanced HF as reported in previous studies, suggesting underutilization. Also, female patients were remarkably more often in INTERMACS profile 1 or 2, suggesting later referral for LVAD therapy. Additional research in female patients is warranted. ispartof: ESC HEART FAILURE vol:10 issue:2 ispartof: location:England status: Published online

Published
2023

28. How does age affect outcomes after left ventricular assist device implantation: results from the PCHF-VAD registry

Author

Radhoe, Sumant P, Veenis, Jesse F, Jakus, Nina, Timmermans, Philippe, Pouleur, Anne-Catherine, Rubís, Pawel, Van Craenenbroeck, Emeline M, Gaizauskas, Edvinas, Barge-Caballero, Eduardo, Paolillo, Stefania, Grundmann, Sebastian, D'Amario, Domenico, Braun, Oscar Ö, Gkouziouta, Aggeliki, Planinc, Ivo, Samardzic, Jure, Meyns, Bart, Droogne, Walter, Wierzbicki, Karol, Holcman, Katarzyna, Flammer, Andreas J, Gasparovic, Hrvoje, Biocina, Bojan, Lund, Lars H, Miličić, Davor, Ruschitzka, Frank, Cikes, Maja, Brugts, Jasper J, Cardiology, University of Zurich, and Brugts, Jasper J

Subjects
Survival, Advanced heart failure, Destination therapy, Heart Failure / epidemiology, 610 Medicine & health, Arrhythmias, Cardiac, Heart-Assist Devices / adverse effects, Thrombosis / etiology, 2705 Cardiology and Cardiovascular Medicine, Age, advanced heart failure, age, destination therapy, left ventricular assist devices, survival, Treatment Outcome, Left ventricular assist devices, 10209 Clinic for Cardiology, Humans, Human medicine, Heart Failure / therapy, Registries, Cardiology and Cardiovascular Medicine, Aged
Abstract

AIMS: Use of left ventricular assist devices (LVADs) in older patients has increased, and assessing outcomes in older LVAD recipients is important. Therefore, this study aimed to investigate associations between age and outcomes after continuous-flow LVAD (cf-LVAD) implantation. METHODS AND RESULTS: Cf-LVAD patients from the multicentre European PCHF-VAD registry were included and categorized into those

Published
2023
Full Text
View/download PDF

30. Sex‐related differences in left ventricular assist device utilization and outcomes: results from the PCHF‐VAD registry

Author

Radhoe, Sumant P., primary, Jakus, Nina, additional, Veenis, Jesse F., additional, Timmermans, Philippe, additional, Pouleur, Anne‐Catherine, additional, Rubís, Pawel, additional, Van Craenenbroeck, Emeline M., additional, Gaizauskas, Edvinas, additional, Barge‐Caballero, Eduardo, additional, Paolillo, Stefania, additional, Grundmann, Sebastian, additional, D'Amario, Domenico, additional, Braun, Oscar Ö., additional, Gkouziouta, Aggeliki, additional, Planinc, Ivo, additional, Macek, Jana Ljubas, additional, Meyns, Bart, additional, Droogne, Walter, additional, Wierzbicki, Karol, additional, Holcman, Katarzyna, additional, Flammer, Andreas J., additional, Gasparovic, Hrvoje, additional, Biocina, Bojan, additional, Milicic, Davor, additional, Lund, Lars H., additional, Ruschitzka, Frank, additional, Brugts, Jasper J., additional, and Cikes, Maja, additional

Published
2022
Full Text
View/download PDF

31. How does age affect outcomes after left ventricular assist device implantation: results from the PCHF‐VAD registry

Author

Radhoe, Sumant P., primary, Veenis, Jesse F., additional, Jakus, Nina, additional, Timmermans, Philippe, additional, Pouleur, Anne‐Catherine, additional, Rubís, Pawel, additional, Van Craenenbroeck, Emeline M., additional, Gaizauskas, Edvinas, additional, Barge‐Caballero, Eduardo, additional, Paolillo, Stefania, additional, Grundmann, Sebastian, additional, D'Amario, Domenico, additional, Braun, Oscar Ö., additional, Gkouziouta, Aggeliki, additional, Planinc, Ivo, additional, Samardzic, Jure, additional, Meyns, Bart, additional, Droogne, Walter, additional, Wierzbicki, Karol, additional, Holcman, Katarzyna, additional, Flammer, Andreas J., additional, Gasparovic, Hrvoje, additional, Biocina, Bojan, additional, Lund, Lars H., additional, Milicic, Davor, additional, Ruschitzka, Frank, additional, Cikes, Maja, additional, and Brugts, Jasper J., additional

Published
2022
Full Text
View/download PDF

33. Acetazolamide in Decompensated Heart Failure with Volume Overload trial ( ADVOR ): baseline characteristics

Author

Mullens, Wilfried, primary, Dauw, Jeroen, additional, Martens, Pieter, additional, Meekers, Evelyne, additional, Nijst, Petra, additional, Verbrugge, Frederik H., additional, Chenot, Fabien, additional, Moubayed, Samer, additional, Dierckx, Riet, additional, Blouard, Philippe, additional, Derthoo, David, additional, Smolders, Walter, additional, Ector, Bavo, additional, Hulselmans, Michaël, additional, Lochy, Stijn, additional, Raes, David, additional, Van Craenenbroeck, Emeline, additional, Vandekerckhove, Hans, additional, Hofkens, Pieter‐Jan, additional, Goossens, Kathleen, additional, Pouleur, Anne‐Catherine, additional, De Ceuninck, Michel, additional, Gabriel, Laurence, additional, Timmermans, Philippe, additional, Prihadi, Edgard A., additional, Van Durme, Frederik, additional, Depauw, Michel, additional, Vervloet, Delphine, additional, Viaene, Els, additional, Vachiery, Jean‐Luc, additional, Tartaglia, Katrien, additional, ter Maaten, Jozine M., additional, Bruckers, Liesbeth, additional, Droogne, Walter, additional, Troisfontaines, Pierre, additional, Damman, Kevin, additional, Lassus, Johan, additional, Mebazaa, Alexandre, additional, Filippatos, Gerasimos, additional, Ruschitzka, Frank, additional, and Dupont, Matthias, additional

Published
2022
Full Text
View/download PDF

35. Head-to-Head Comparison of Global and Regional Two-Dimensional Speckle Tracking Strain Versus Cardiac Magnetic Resonance Tagging in a Multicenter Validation Study

Author

Amzulescu, Mihaela Silvia, Langet, Hélène, Saloux, Eric, Manrique, Alain, Boileau, Laurianne, Slimani, Alisson, Allain, Pascal, Roy, Clotilde, de Meester, Christophe, Pasquet, Agnès, De Craene, Mathieu, Vancraeynest, David, Pouleur, Anne-Catherine, Vanoverschelde, Jean-Louis J., and Gerber, Bernhard L.

Published
2017
Full Text
View/download PDF

38. Prognostic implications of paradoxical low gradient severe aortic stenosis: A comprehensive analysis from a large multicentric registry

Author

De Azevedo, David, primary, De Meester, Christophe, additional, Hanet, Vincent, additional, Altes, Alexandre, additional, Pouleur, Anne-Catherine, additional, Pasquet, Agnès, additional, Gerber, Bernhard, additional, Maréchaux, Sylvestre, additional, Tribouilloy, Christophe, additional, Vanoverschelde, Jean-Louis, additional, and Vancraeynest, David, additional

Published
2022
Full Text
View/download PDF

40. Impact of 2021 ESC/EACTS surgical triggers on postoperative survival in aortic regurgitation: Insights from the AVIATOR registry

Author

Hanet, Vincent, primary, De Azevedo, David, additional, Krug, Pauline, additional, Altes, Alexandre, additional, Schäfers, Hans-Joachim, additional, Lansac, Emmanuel, additional, Hamamsy, Ismail El, additional, Vojácek, Jan, additional, Contino, Monica, additional, Pouleur, Anne-Catherine, additional, Beauloye, Christophe, additional, Pasquet, Agnès, additional, Vanoverschelde, Jean-Louis, additional, Vancraeynest, David, additional, and Gerber, Bernhard, additional

Published
2022
Full Text
View/download PDF

44. Innovations 2021 en cardiologie

Author

Pasquet, Agnes, Pouleur, Anne-Catherine, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, and UCL - (SLuc) Centre des cardiopathies congénitales de l'adulte

Subjects
Heart failure with mildly reduced ejection fraction, Heart failure with preserved ejection fraction, Heart failure with reduced ejection fraction
Published
2022

45. L’évaluation de la fonction ventriculaire droite à l’échographie et son impact pronostique dans l’insuffisance cardiaque à fonction préservée: état des lieux et perspectives

Author

Lejeune, Sibille, Pouleur, Anne-Catherine, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, and UCL - (SLuc) Service de pathologie cardiovasculaire

Abstract

L’insuffisance cardiaque à fraction d’éjection préservée est un syndrome défini par la présence de symptômes d’insuffisance cardiaque en l’absence d’une fraction d’éjection ventriculaire gauche altérée. En effet, le cœur de ces patients se contracte normalement mais souffre d’un défaut de relaxation, entraînant une élévation des pressions de remplissage pour maintenir un débit satisfaisant. Cette élévation de pression peut se répercuter en amont sur la circulation pulmonaire et sur la fonction du ventricule droit. L’altération de la fonction du ventricule droit est un facteur de mauvais pronostique mais son évaluation échographique reste difficile vu sa géométrie et sa position dans le thorax. De ce fait, une recherche active est en cours pour trouver de nouvelles méthodes de mesure fiables. Parmi celles-ci, l’étude de la déformation myocardique par suivi de marqueurs acoustiques échographiques (speckle tracking strain).

Published
2022

46. Echografische evaluatie van de rechterventrikelfunctie en prognostische waarde ervan bij hartfalen met gevrijwaarde functie: stand van zaken en perspectieven

Author

Lejeune, Sibille, Pouleur, Anne-Catherine, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, and UCL - (SLuc) Service de pathologie cardiovasculaire

Abstract

Hartfalen met gevrijwaarde ejectiefractie is een syndroom dat wordt gekenmerkt door symptomen van hartfalen zonder daling van de linkerventrikelejectiefractie. Het hart van die patiënten trekt normaal samen, maar de relaxatie verloopt niet correct, waardoor de vullingsdrukken stijgen om het hartdebiet op peil te houden. Die drukstijging kan stroomopwaarts invloed uitoefenen op de longcirculatie en op de functie van het rechterventrikel. Een verstoorde rechterventrikelfunctie is prognostisch ongunstig. Echografische evaluatie van de rechterventrikelfunctie is echter moeilijk gezien de geometrie en de positie van het rechterventrikel in de thorax. Daarom wordt actief gezocht naar nieuwe, betrouwbare meetmethoden. Eén daarvan is onderzoek van de vervorming van het myocard door tracking van echografische akoestische markers (speckle tracking strain).

Published
2022

48. Association of Plasma Myeloperoxidase with Inflammation and Diabetic status in HFpEF.

Author

Lejeune, Sibille, Ginion, Audrey, Menghoum, Nassiba, Vancraeynest, David, Pasquet, Agnes, Gerber, Bernhard L., Horman, Sandrine, Beauloye, Christophe, and Pouleur, Anne-Catherine

Abstract

Background: Inflammation and oxidative stress are thought to play an important role in the pathophysiology of heart failure with preserved ejection fraction (HFpEF) through the development of endothelial dysfunction. Myeloperoxidase (MPO) functions as a link between oxidative stress and inflammation and is an interesting therapeutic target. The objective of this observational cohort study was to compare MPO levels between HFpEF and old controls, to define clinical characteristics associated with high levels of MPO and to assess the relation between MPO levels and vascular function. Methods: Patients with HFpEF (N = 55) and controls >60 years (N = 18) were prospectively included. All subjects underwent complete echocardiography and blood sampling. MPO levels were dosed by ELISA assay. Effective arterial elastance (Ea) and peripheral arterial tonometry (EndoPAT reactive hyperemia index RHI and augmentation index AIx) were used to assess vascular function. Characteristics between groups defined by the median of MPO were compared using independent samples t-test or chi square test. Results: Patients with HFpEF (80 ± 8.7 years, 65% female) had higher levels of MPO compared to controls (75 ± 5.0 years, 72% female) (34.7 ng/mL [22.7; 44.0] vs 22.6 [18.2; 32.0], p = 0.026). MPO levels were correlated with markers of inflammation; C-reactive protein (Pearson's R = 0.46, p = 0.001) and neutrophile to lymphocyte ratio (R = 0.36, p = 0.031) and with signs of left ventricular (LV) remodelling and elevated filling pressures, namely NT-proBNP levels (R = 0.32, p = 0.019), decreased LV ejection fraction (LVEF, R = -0.36, p = 0.008) and E/e' ratio (R = 0.35, p = 0.011). HFpEF patients with levels of MPO above the median were more often men (48% vs 21%, p = 0.037) and suffered more often from diabetes (48% vs 18%, p = 0.017). Intriguingly, they had lower indices of vascular stiffness (augmentation index 11.1 [0.1; 30.7] vs 19.9 [10.5; 33.4], p = 0.018 and arterial elastance Ea 2.06 ± 0.676 vs 2.43 ± 0.721, p = 0.065) and there was no difference in endothelial function (1.82 [1.34; 2.30] vs 1.66 [1.32; 1.95], p = 0.55). Conclusions: HFpEF patients have higher levels of MPO than controls, reflecting leukocyte activation and oxidative stress. Among patients, high levels of MPO are associated with male sex, diabetic status, subtle left ventricular dysfunction and pronounced diastolic dysfunction. The association between oxidative stress and vascular stiffness, on the other hand could not be demonstrated. Clinical Trial Registration: Clinical trial NCT03197350. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results